

# Non-Clinical research for the development of dry macular degeneration

Mother's Pharmaceutical Co., Ltd.



OPHTHALMOLOGY	Preclinical
Product Type	Small molecule(NCE)
Indication	Dry Age-Related Macular Degeneration (Dry-AMD)
Target	RIPK1(Receptor-interacting serine/threonine protein kinase 1)
MoA(Mechanism of Action)	Inhibition of RIPK1 → Inhibition of retinal cell death caused by apoptosis and necroptosis
Competitiveness	<ul style="list-style-type: none"> <li>• MTS-001 is a first-in-class RIPK1 inhibitor that effectively inhibits different forms of cell death which is one of the main causes of dry age-related macular degeneration.</li> <li>• MTS-001 also provides protective effects against aging and oxidative stress.</li> <li>• The target patient population is expected to include early to late dry age-related macular degeneration.</li> <li>• Notably, MTS-001 is developed as an eye drop, maximizing patient convenience and minimizing the inconveniences and side effects of intravitreal injection like those used in wet age-related macular degeneration treatments.</li> </ul>
Development Stage	Preclinical
Route of Administration	Eye drop